SEC FIlings

06 Feb

SEC FIlings

Current report

February 6, 2023
Posted by Jitendra

03 Feb

SEC FIlings

Prospectus [Rule 424(b)(3)]

February 3, 2023
Posted by Jitendra

03 Feb

SEC FIlings

Prospectus [Rule 424(b)(3)]

February 3, 2023
Posted by Jitendra

03 Feb

SEC FIlings

Prospectus [Rule 424(b)(3)]

February 3, 2023
Posted by Jitendra

02 Feb

SEC FIlings

Current report

February 2, 2023
Posted by Jitendra

02 Feb

SEC FIlings

Current report

February 2, 2023
Posted by Jitendra

30 Jan

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 30, 2023
Posted by Ulisses

30 Jan

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 30, 2023
Posted by Ulisses

30 Jan

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 30, 2023
Posted by Ulisses

30 Jan

SEC FIlings

Current report

January 30, 2023
Posted by Ulisses

Current report

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Current report

Current report

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Current report

Gloperba Launch – Nasdaq-2024

A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain

Gout Awareness Day – May 22

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch